PubMed COVID-19 Clinical Care

No abstract

CONCLUSIONS: Responding Canadian paediatricians are knowledgeable and comfortable with current screen time guidelines in Canada. Despite this, there is increasing concern with health outcomes associated with screen use. These results highlight

CONCLUSION: During the lockdown, the respondents generally indicated positive attitudes towards the communication course, the mentors and the inclusion of physician-patient communication as a topic in medical education. The students and mentors

CONCLUSION: The main factors affecting allergic diseases were likely related to increased time at home, preventive measures against COVID-19, and refraining from doctor visits. Children with allergies were affected by changes in social conditions

The long-term health effects of SARS-CoV-2, termed Post-Acute Sequelae of COVID-19 (PASC), are quickly evolving into a major public health concern, but the underlying cellular and molecular etiology remain poorly defined. There is growing evidence

CONCLUSION: Since patient-centered care and SDM have particular relevance in rare diseases in general, we believe our findings could be transferrable and applicable in the management of other rare diseases.

Objective: To investigate the prevalence of depression, anxiety, and insomnia among hospital staff during the second wave of the COVID-19 pandemic and to explore changes in the rate of psychological morbidities across the first 2 waves.

As a result of the COVID-19 (coronavirus) disease due to SARS-CoV2 becoming a pandemic, it has spread over the globe. It takes time to evaluate the results of the laboratory tests because of the rising number of cases each day. Therefore, there are

Numerous US transplant centers require solid organ transplantation candidates to be vaccinated against COVID-19 to be active on the UNOS waiting list. This study examined characteristics of adult patients on one center's kidney transplantation

Pre-exposure prophylaxis with tixagevimab/cilgavimab was considered a useful strategy to protect immunocompromised patients from COVID-19 based on the phase 3 PROVENT trial conducted between November 2020 and March 2021. However, after late 2021, the